Guggenheim Starts Verve Therapeutics (VERV) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VERV Hot Sheet
Price: $11.13 --0%
Rating Summary:
4 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
4 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Guggenheim analyst Etzer Darout initiates coverage on Verve Therapeutics (NASDAQ: VERV) with a Buy rating and a price target of $84.00.
For an analyst ratings summary and ratings history on Verve Therapeutics click here. For more ratings news on Verve Therapeutics click here.
Shares of Verve Therapeutics closed at $46.00 yesterday.
You May Also Be Interested In
- Craig-Hallum Starts OraSure Technologies (OSUR) at Buy, PT $7
- Oppenheimer Starts Karman Holdings Inc (KRMN) at Outperform
- Tigress Financial Partners Starts Broadcom Limited (AVGO) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
